D Trapani, M A Franzoi, H J Burstein, L A Carey, S Delaloge, N Harbeck, D F Hayes, K Kalinsky, L Pusztai, M M Regan, I Sestak, T Spanic, J Sparano, S Jezdic, N Cherny, G Curigliano, F Andre
BACKGROUND: The landscape of clinical trials testing risk-adapted modulations of cancer treatments is complex. Multiple trial designs, endpoints, and thresholds for non-inferiority have been used; however, no consensus or convention has ever been agreed to categorise biomarkers useful to inform the treatment intensity modulation of cancer treatments. METHODS: An expert subgroup under the European Society for Medical Oncology (ESMO) Precision Medicine Working Group shaped an international collaborative project to develop a classification system for biomarkers used in the cancer treatment de-intensification, based on a tiered approach...
May 3, 2022: Annals of Oncology: Official Journal of the European Society for Medical Oncology